Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03041311
Title Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | ESP


No variant requirements are available.